Purchase Option

$ 3000
$ 4400
$ 4000
$ 6000

Beta-Thalassemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Overview:

Beta-Thalassemia is an inherited blood disorder characterized by decreased levels of functional hemoglobin, which is the iron containing protein present in red blood cells that carries oxygen to the cells throughout the body. People with Beta-Thalassemia will be suffering from lack of oxygen supply in body and also shortage of red blood cells and will be at the increased risk of developing abnormal blood clots.

Symptoms of Beta-Thalassemia includes pale skin, jaundice, enlarged spleen, liver and heart, delayed puberty. Beta-Thalassemia can be diagnosed by molecular and genetic tests, blood tests etc. Treatment of Beta-Thalassemia includes frequent blood transfusions, bone marrow transplant, surgery to remove spleen or gallbladder and medications.

 

Segmentation:

By Trial Phase, Beta-Thalassemiapipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company, Beta-Thalassemiapipeline drugs are segmented as:

  • Celgene Pharmaceuticals
  • bluebird bio.Inc
  • GlaxoSmithKline
  • Acceleron Pharma, Inc.
  • Sanofi
  • Novartis
  • HemaQuest Pharmaceuticals Inc.
  • Hoffmann-La Roche
  • FerroKinBioSciences, Inc.
  • Others

By Drugs, Beta-Thalassemia pipeline drugs are segmented as:

  • LentiGlobin
  • Deferitrin
  • Desferoxamine
  • Bitopertin
  • Deferasirox
  • Luspatercept
  • Zoledronic acid
  • Ambrisentan
  • Others

By Type of Condition, Beta-Thalassemia pipeline drugs are segmented as:

  • Thalassemia Major (Cooley's anemia)
  • Thalassemia Intermedia

By Route of Administration, Beta-Thalassemiapipeline drugs are segmented as:

  • Oral
  • Parenteral

 

Space Analysis:

  • In October 2017, Sangamo Therapeutics and Bioverativreceived U.S.FDA IND acceptance to begin human clinical studies of ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia.
  • In September 2016, bluebird bio, Inc. commenced a phase III global multi center study of its HGB-207  in patients with transfusion-dependent beta-thalassemia with non-?0/?0genotypes
  • In May 2015, Luspatercept of Celgene Corporation and Acceleron Pharma Inc. was granted Fast track designations by U.S. FDA for two separate indications, for the treatment of patients with transfusion dependent beta-thalassemia and patients with non-transfusion dependent beta-thalassemia. Luspatercept is a modified activin receptor type IIB fusion protein that acts as a ligand trap for members of the Transforming Growth Factor-Beta (TGF-beta) superfamily involved in the late stages of erythropoiesis (red blood cell production). Luspatercept regulates late-stage erythrocyte (red blood cell) precursor cell differentiation and maturation
 

Report Description:

Beta-ThalassemiaDisease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Beta-Thalassemia treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Beta-Thalassemia disease pipeline drugs development. This report studies the dynamics of the Beta-Thalassemia Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Beta-Thalassemia disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on the each drug candidates in the clinical trial phases

Location

GEOGRAPHY

PBI Location Map

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
LOCATION

Geography

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

  1. Table of Content
  2. Executive Summary
  3. Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market Introduction
    • Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market – Taxonomy
    • Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market –Definitions
      • Trial Phase
      • Drugs
      • Type of Condition
      • Route of Administration
  1. Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market Dynamic Factors - Impact Analysis
    • Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market – Competition Landscape
    • Epidemiology
  2. Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market Analysis,2013 - 2017 and Forecast, 2018 – 2024
    • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market OpportunityAnalysis
  3. Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market, By Trial Phase, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Preclinical Trials
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 1
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 2
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 3
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 4
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market Forecast, By Drugs,2013 - 2017 and Forecast, 2018 – 2024
    • LentiGlobin
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Deferitrin
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Desferoxamine
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Bitopertin
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Deferasirox
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Luspatercept
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Zoledronic acid
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Ambrisentan
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market Forecast, By Type of Condition, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Thalassemia Major (Cooley’s anemia)
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Thalassemia Intermedia
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market Forecast, By Route of Administration, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Oral
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Parenteral
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market Forecast, By Region, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • North America
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Beta-Thalassemia Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Trial Phase, By Drugs, By Type of Condition, By Route of Administration, and Region, 2018 – 2024
  2. North America Beta-Thalassemia Disease Pipeline Drugs Assessment MarketAnalysis,2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Drugs Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • LentiGlobin
      • Deferitrin
      • Desferoxamine
      • Bitopertin
      • Deferasirox
      • Luspatercept
      • Zoledronic acid
      • Ambrisentan
      • Others
    • Type of Condition Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Thalassemia Major (Cooley’s anemia)
      • Thalassemia Intermedia
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Country Analysis 2016 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • S.
      • Canada
    • North America Beta-Thalassemia Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Trial Phase, By Drugs, By Type of Condition, By Route of Administration, and Country, 2018 – 2024
    • North America Beta-Thalassemia Disease Pipeline Drugs Assessment Market Dynamics – Trends
  3. Europe Beta-Thalassemia Disease Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Drugs Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • LentiGlobin
      • Deferitrin
      • Desferoxamine
      • Bitopertin
      • Deferasirox
      • Luspatercept
      • Zoledronic acid
      • Ambrisentan
      • Others
    • Type of Condition Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Thalassemia Major (Cooley’s anemia)
      • Thalassemia Intermedia
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Beta-Thalassemia Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Trial Phase, By Drugs, By Type of Condition, By Route of Administration, and Country, 2018 – 2024
    • Europe Beta-Thalassemia Disease Pipeline Drugs Assessment Market Dynamics – Trends
  4. Asia-Pacific Beta-Thalassemia Disease Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Drugs Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • LentiGlobin
      • Deferitrin
      • Desferoxamine
      • Bitopertin
      • Deferasirox
      • Luspatercept
      • Zoledronic acid
      • Ambrisentan
      • Others
    • Type of Condition Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Thalassemia Major (Cooley’s anemia)
      • Thalassemia Intermedia
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Country Analysis2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia-Pacific
    • Asia-Pacific Beta-Thalassemia Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Trial Phase, By Drugs, By Type of Condition, By Route of Administration, and Country, 2018 – 2024
    • Asia-Pacific Beta-Thalassemia Disease Pipeline Drugs Assessment Market Dynamics – Trends
  5. Latin America Beta-Thalassemia Disease Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Drugs Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • LentiGlobin
      • Deferitrin
      • Desferoxamine
      • Bitopertin
      • Deferasirox
      • Luspatercept
      • Zoledronic acid
      • Ambrisentan
      • Others
    • Type of Condition Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Thalassemia Major (Cooley’s anemia)
      • Thalassemia Intermedia
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Beta-Thalassemia Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Trial Phase, By Drugs, By Type of Condition, By Route of Administration, and Country, 2018 – 2024
    • Latin America Beta-Thalassemia Disease Pipeline Drugs Assessment Market Dynamics – Trends
  6. Middle East and Africa Beta-Thalassemia Disease Pipeline Drugs Assessment Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024 (Revenue, USD Mn)
    • Trial Phase Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Drugs Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • LentiGlobin
      • Deferitrin
      • Desferoxamine
      • Bitopertin
      • Deferasirox
      • Luspatercept
      • Zoledronic acid
      • Ambrisentan
      • Others
    • Type of Condition Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Thalassemia Major (Cooley’s anemia)
      • Thalassemia Intermedia
    • Route of Administration Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Country Analysis 2013 - 2017 and Forecast 2018 - 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Beta-Thalassemia Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Trial Phase, By Drugs, By Type of Condition, By Route of Administration, and Country, 2018 – 2024
    • MEA Beta-Thalassemia Disease Pipeline Drugs Assessment Market Dynamics – Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Trial Phase& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Celgene Pharmaceuticals
      • bluebird bio.Inc
      • GlaxoSmithKline
      • Acceleron Pharma, Inc.
      • Sanofi
      • Novartis
      • HemaQuest Pharmaceuticals Inc.
      • Hoffmann-La Roche
      • FerroKinBioSciences, Inc.
  1. Research Methodology
  2. Key Assumptions and Acronyms

 

  1. Disclaimer
  2. The above mentioned segmentation is tentative; it is changed according to client’s requirement, or research feasibility.
  • Celgene Pharmaceuticals
  • bluebird bio.Inc
  • GlaxoSmithKline
  • Acceleron Pharma, Inc.
  • Sanofi
  • Novartis
  • HemaQuest Pharmaceuticals Inc.
  • Hoffmann-La Roche
  • FerroKinBioSciences, Inc.